Verdicts genuinely change. Free email alert the moment SGMOQ's does — no target price to set, unlike "Alert" above.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
SGMOQ is currently considered not halal (non-compliant), per In-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
449 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →
Computed from published company financials, balance sheet as of 2026-03-31. SGMOQ files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 29.87% | 30.00% | Pass |
| Interest-bearing investments | 39.17% | 30.00% | Fail |
| Non-permissible income | 3.29% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 35.08% | 33.00% | Fail |
| Interest-bearing investments | 46.00% | 33.00% | Fail |
| Non-liquid assets | 52.54% | at least 20.00% | Pass |
| Non-permissible income | 3.29% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 35.08% | 33.33% | Fail |
| Cash + interest-bearing securities | 46.00% | 33.33% | Fail |
| Accounts receivable | 47.46% | 33.33% | Fail |
| Non-permissible income | 3.29% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass |
| Cash + interest-bearing securities | 46.00% | 33.33% | Fail |
| Accounts receivable | 47.46% | 50.00% | Pass |
| Non-permissible income | 3.29% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 7.42% | 33.00% | Pass |
| Cash + interest-bearing securities | 9.73% | 33.00% | Pass |
| Accounts receivable | 0.31% | 33.00% | Pass |
| Non-permissible income | 3.29% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 8.00% | 33.00% | Pass |
| Cash + interest-bearing securities | 10.49% | 49.00% | Pass |
| Accounts receivable | 0.33% | 49.00% | Pass |
| Non-permissible income | 3.29% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 8.00% | 33.33% | Pass |
| Cash + interest-bearing securities | 10.49% | 33.33% | Pass |
| Accounts receivable | 10.83% | 49.00% | Pass |
| Non-permissible income | 3.29% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
Read from SGMOQ's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $39.6M | 2025-12-31 | RevenueFromContractWithCustomerExcludingAssessedTax |
| Interest-bearing debtShort and long-term borrowings | $0 | 2026-03-31 | no debt tag reported in 3+ years (treated as $0) |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $27.6M | 2026-03-31 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
| Total assetsBalance sheet total | $60.0M | 2026-03-31 | Assets |
| Market capDenominator for AAOIFI | $70.4M | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $151.5M | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $169.5M | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $1.3M | 2025-12-31 | InvestmentIncomeInterest |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Verdict history for SGMOQ. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
Tracked since 2026-09-07.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 23.80 | BUY |
| Stochastic %K (14) | 64.29 | NEUTRAL |
| CCI (20) | -232.46 | BUY |
| Williams %R (14) | -35.71 | NEUTRAL |
| MACD (12,26,9) | -0.00 | SELL |
| ROC (10) | -28.57 | SELL |
| Momentum (10) | -0.04 | SELL |
| EMA (10) | 0.13 | SELL |
| SMA (10) | 0.14 | SELL |
| EMA (20) | 0.14 | SELL |
| SMA (20) | 0.14 | SELL |
| EMA (30) | 0.14 | SELL |
| SMA (30) | 0.14 | SELL |
| EMA (50) | 0.14 | SELL |
| SMA (50) | 0.15 | SELL |
| EMA (100) | 0.16 | SELL |
| SMA (100) | 0.13 | SELL |
| EMA (200) | 0.25 | SELL |
| SMA (200) | 0.22 | SELL |
Healthcare · Biotechnology
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. ALS and Frontotemporal Lobar Degeneration; Takeda Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California. On June 23, 2026, Sangamo Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 42 |
| ⏰ 4H | BEARISH | 26 |
| 🕐 1H | RANGING | 98 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
The questions worth asking about any verdict on this page, answered plainly.
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-10-13 · Asset managers net 915835 (+9220)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.